Outgoing ProVision CEO Mr Steven Johnston believes the future of independent optometry in Australia is bright if practices continue to embrace technology that allows the time to offer a patient experience that can’t be replicated anywhere else. Read more
The Vision Eye Institute (VEI) has launched the new not-for-profit Future Vision Foundation to support ophthalmic research, as well as the Vision Hospital Group to bring its day surgery network under one banner, to mark its 20th anniversary. Read more
Ivantis has revealed new data from its five-year HORIZON pivotal trial showing its Hydrus Microstent device lowers the rate of visual field loss by 47% versus cataract surgery alone. Read more
Attracting and retaining patients with contact lens products has become increasingly difficult with the rise of online retailers. But Menicon Australia is one major manufacturer choosing to stick by independents with a portfolio spanning across daily disposables and specialty contact lenses.
Australian biotechnology company PYC Therapeutics has advanced its RNA platform closer to human trials after determining safe and well tolerated doses of its co-lead drug candidate for retinitis pigmentosa 11 (RP11) in monkeys. Read more
After a career spanning more than 21 years at Zeiss, Mr Joe Redner has departed the company, handing the reins of the Australasia business to Dr Rene Hessling. Read more
Hoya Vision Care Australia & New Zealand has unveiled a new Oliver Wolfe Junior frame collection – suitable for the company’s new myopia control spectacle lens – in response to practice requests to extend the brand’s popular adult range. Read more
Australian optical chain Bailey Nelson has opened its 50th retail store in the Castle Towers Shopping Centre in Sydney’s burgeoning northwest. Read more
Melbourne-based next generation Hyperparallel OCT manufacturer Cylite has further expanded its R&D team with the appointment of optical physicist Dr Clare Manderson. Read more
Multinational ophthalmic company Alcon has agreed to acquire privately-owned Californian firm Ivantis – and its Hydrus Microstent minimally invasive glaucoma surgery (MIGS) device – for an initial US$475 million (AU$640 m). Read more